Alaunos Therapeutics Faces Delisting Concerns
Ticker: TCRT · Form: 8-K · Filed: Apr 11, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Alaunos Therapeutics might get delisted - big trouble for shareholders.
AI Summary
Alaunos Therapeutics, Inc. filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as ZIOPHARM ONCOLOGY INC, is based in Houston, TX.
Why It Matters
This filing indicates potential issues with Alaunos Therapeutics' compliance with stock exchange listing standards, which could lead to its shares being removed from trading.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- ZIOPHARM ONCOLOGY INC (company) — Former company name
- April 7, 2025 (date) — Date of earliest event reported
- April 11, 2025 (date) — Filing date
- Houston, TX (location) — Principal executive offices
FAQ
What is the primary reason for Alaunos Therapeutics' 8-K filing?
The primary reason is a notice of delisting or failure to satisfy a continued listing rule or standard.
When was the earliest event reported in this filing?
The earliest event reported was on April 7, 2025.
What is Alaunos Therapeutics' former company name?
Alaunos Therapeutics, Inc. was formerly known as ZIOPHARM ONCOLOGY INC.
Where are Alaunos Therapeutics' principal executive offices located?
The principal executive offices are located at 2617 Bissonnet St Suite 225, Houston, TX 77005.
What is the SEC file number for Alaunos Therapeutics?
The SEC file number for Alaunos Therapeutics is 001-33038.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 11, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).